Seed and Agri-Biotech Stocks and Companies in India

The largest Seed and Agri-Biotech stocks in India by market value are Advanced Enzyme Technologies (₹3,117 crore), Rossari Biotech (₹2,329 crore) and Bombay Super Hybrid Seeds (₹883 crore), at prices of 4 Nov 2026.

• Advanced Enzyme Technologies: ₹278.40 | market value ₹3,117 crore | P/E 19.2
• Rossari Biotech: ₹420.40 | market value ₹2,329 crore | P/E 15.3
• Bombay Super Hybrid Seeds: ₹84.15 | market value ₹883 crore | P/E 30.7

Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 4 Nov 2026; the score list below uses the weekly figures.

All 3 listed Indian Seeds/Tissue Culture/Bio Technology companies are named here, largest first. This is the set of companies people mean when they search for a Nifty Seeds/Tissue Culture/Bio Technology index; NSE publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one. One large company cannot set the reading.

1. Advanced Enzyme Technologies Ltd₹2,950 cr
2. Rossari Biotech Ltd₹2,210 cr
3. Bombay Super Hybrid Seeds Ltd₹873 cr

3 Seed and Agri-Biotech companies in the Seeds/Tissue Culture/Bio Technology industry group have a page on Sector Alpha, by market value as of 30 October 2026, and all 3 are listed below, largest first. The largest is Advanced Enzyme Technologies (₹2,951 crore) and the smallest with a market value is Bombay Super Hybrid Seeds.

Download all 3 Seed and Agri-Biotech companies (CSV)

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 41% behind NIFTY 500. Earnings across its companies grew 9% on average over the last four reported quarters.

0 of 3 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high).

Not ahead of NIFTY 500 on the three-month view this week; 0 of the 3 companies in the industry index above their 200-day average (no change from four weeks earlier); 0 of those 3 pass the momentum test (no change from four weeks earlier); earnings rising at 3 of the 3 that report earnings.

Behind NIFTY 500 by −18.9% over a year, with participation off the floor of its own 26-week range. Earnings confirming, 3 of 3 members have higher trailing twelve-month earnings than a year ago.

Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 3 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.

Seeds/Tissue Culture/Bio Technology has done worse than the NIFTY 500 by 20.4% over the last 52 weeks. Over 13 weeks the gap is a shortfall of 5.9%. Bombay Super Hybrid Seeds Ltd is the strongest against the sector itself at +3.8%.

Seeds/Tissue Culture/Bio Technology has done worse than the NIFTY 500 by 20.4% over 52 weeks and by 5.9% over 13 weeks. 0 of 3 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 1 of 3 is ahead of the industry itself.

A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.

Advanced Enzyme Technologies Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 79.3% evidence confidence.

Advanced Enzyme Technologies Ltd has the strongest one-year price move in Seeds/Tissue Culture/Bio Technology at −14.4%. Bombay Super Hybrid Seeds Ltd leads on relative strength against the NIFTY, at −6.5%. 0 of 3 companies we track are ahead of the index on that measure. Every line covers 313 weekly closes through 30 October 2026.

Price and relative strength

Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.

RS vs sector: The same measure taken against Seeds/Tissue Culture/Bio Technology itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.

Biggest one-year moves

Strongest against NIFTY 500

Strongest against the sector itself

Over 2015 to 2026 the sector grew revenue from 253 cr to 3486 cr (+1278%), yet profit only grew from 51 cr to 350 cr (+586%), the wedge is margins: operating margin bled from a 39.04% peak (2016) down to 15.81% latest (2026), and profit margin roughly halved from a 21.63% peak (2016) to 10.04% now. Caveat: BRONZE data confidence, only 3 constituents, so the index is thin and idiosyncratic.

From our industry review of 5 June 2026. A newer review (10 October 2026) did not cover Seeds/Tissue Culture/Bio Technology, so this is the latest we have.

2 of 3 Seeds/Tissue Culture/Bio Technology companies held a results call for April to June 2026. Advanced Enzyme Technologies guided: FY27 consolidated revenue growth in double digits; US business growth not expected to exceed approximately 8-10%, with approximately 8% by year-end.

From the results calls for April to June 2026.

Big funds, foreign and Indian, cut their stake by 1.3 points over the last two quarters. Founders and promoters kept theirs about the same.

• Spending on new plants and equipment was ₹298 crore in the last 12 months, 7% more than a year before.
• Projects still being built grew 38% in a year.

Big funds = foreign and Indian institutions, change in their share of ownership across 3 Seeds/Tissue Culture/Bio Technology companies, in percentage points.

Ownership and spending as of 10 October 2026.

Rossari Biotech Ltd has the highest Revenue among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at ₹2,662 crore. Advanced Enzyme Technologies Ltd is next at ₹782 crore. Bombay Super Hybrid Seeds Ltd has the highest Revenue growth at 22.4%, so level and change sit with different companies. Its Revenue series carries 20 reported observations across the 20-quarter window.

What the numbers say: Rossari Biotech Ltd is the largest at ₹2,662 crore, 240.4% ahead of Advanced Enzyme Technologies Ltd. Bombay Super Hybrid Seeds Ltd's growth is 22.4% from a ₹433 crore base, with 20 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.

What this means: Rossari Biotech Ltd is the size to compare against; Bombay Super Hybrid Seeds Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.

This conclusion weakens if: Rossari Biotech Ltd's growth falls below Bombay Super Hybrid Seeds Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenue · company comparison

Revenue · largest

Revenue growth · fastest growers

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.

Advanced Enzyme Technologies Ltd has the highest OPM among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 34%. Rossari Biotech Ltd is next at 12%. The same company also has the highest Margin change, at +1 percentage points. 3 of 3 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Advanced Enzyme Technologies Ltd leads both opm at 34% and margin change at +1 percentage points.

What this means: Advanced Enzyme Technologies Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

Operating margin · company comparison

OPM · highest

Margin change · fastest expanders

All-company data · latest reported quarter

Advanced Enzyme Technologies Ltd has the highest Net profit among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at ₹178 crore. Rossari Biotech Ltd is next at ₹153 crore. The same company also has the highest Profit growth, at 17.9%. 3 of 3 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Advanced Enzyme Technologies Ltd earns the most, ₹178 crore of profit over the last 12 months, 16.3% above Rossari Biotech Ltd. A fast rate from a small base matters less than a large profit that keeps coming.

What this means: Advanced Enzyme Technologies Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profit · company comparison

Net profit · largest

Profit growth · fastest growers

All-company data · latest reported quarter

Bombay Super Hybrid Seeds Ltd has the highest ROCE among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 16%. Advanced Enzyme Technologies Ltd is next at 14%. Advanced Enzyme Technologies Ltd has the highest ROCE change at +1 percentage points, so level and change sit with different companies. Its ROCE series carries 16 reported observations across the 20-quarter window.

What the numbers say: Bombay Super Hybrid Seeds Ltd leads ROCE at 16%, 2 percentage points above Advanced Enzyme Technologies Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.

What this means: Bombay Super Hybrid Seeds Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

Return on capital · company comparison

Withheld from this chart: Advanced Enzyme Technologies Ltd (ADVENZYMES): its two data sources disagree by up to 4% on reported income across 15 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn, the gap is a decision, not missing data.

ROCE · highest

ROCE change · fastest improvers

All-company data · latest reported quarter

Rossari Biotech Ltd has the lowest PEG among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 1.42×. Bombay Super Hybrid Seeds Ltd is next at 2.15×. The same company also has the lowest P/E, at 14.5×. 2 of 3 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Rossari Biotech Ltd has the lowest comparable PEG at 1.42×, 34% below Bombay Super Hybrid Seeds Ltd. That would need today's multiple, the company's own history and steady growth to agree.

What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

Valuation · company comparison

PEG · lowest PEG

P/E · lowest P/E

All-company data · latest reported quarter

Seeds/Tissue Culture/Bio Technology companies show up on one of our India lists. The most are on the penny stocks list (1 company).

This Seeds/Tissue Culture/Bio Technology comparison names 6 specific ways its own evidence can mislead, all listed below. All 3 companies here report on comparable dates, so no rank carries a stale marker. 1 has second-source figures left out because the two sources disagree. 1 of the 5 ranked sections has fewer than three usable current readings.

Keep these limits visible

• A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
• A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
• The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
• An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
• 1 company is missing from the second-source figures on purpose: the two sources disagree, so nothing from the second is drawn. Those rows have less evidence; that does not make the business weaker.
• Thin comparisons: Valuation have fewer than three usable current readings.

This comparison is built from the reported filings of 3 Seeds/Tissue Culture/Bio Technology companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 30 October 2026.

1 of 3 companies has a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Advanced Enzyme Technologies Ltd (ADVENZYMES): its two data sources disagree by up to 4% on reported income across 15 comparable periods, so its derived ratios are withheld.

These 23 answers restate the Seeds/Tissue Culture/Bio Technology comparison above in question form. Every one is computed from the same 3 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 30 October 2026. Nothing here is estimated, and none of it is a recommendation.